德孚在中国

9 7 3 1 6

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

EGFR   突变作为非小细胞肺癌的一个预后与预测标志

 

Authors Fang S, Wang Z

Published Date September 2014 Volume 2014:8 Pages 1595—1611

DOI http://dx.doi.org/10.2147/DDDT.S69690

Received 19 June 2014, Accepted 17 July 2014, Published 26 September 2014

Abstract: Non-small-cell lung cancer (NSCLC) has entered the age of individual treatment, and increasing point mutations of specific oncogenes and rearrangement of some chromosomes are biomarkers used to predict the therapeutic effect of targeted therapy. At present, there is a consensus among clinicians that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown favorable efficacy in NSCLC patients with EGFR  mutation, and some relevant research has suggested that the presence of EGFR  mutations is a favorable prognostic marker. However, the association of EGFR  mutation status with the responsiveness to conventional chemotherapy agents and survival in NSCLC patients is still unclear. This review provides an overview of and assesses the role of EGFR  as a prognostic marker for postoperative patients and as a predictive marker for response to cytotoxic chemotherapy. In addition, we review the comparison of response to chemotherapy between EGFR  mutations in exon 19 and in exon 21 and the predictive role of p.T790M mutation.
Keywords: epidermal growth factor receptor, prediction, prognosis






Download Article[PDF]